•FDA clears Heidelberg's new SPECTRALIS software release•Alkeus begins dosing in global phase 3 Stargardt trial on oral gildeuretinol•Alvotech resubmits BLA for proposed Eylea biosimilar•CooperVision completes global enrollment for largest pediatric myopia control study•FDA approves Lupin's Lucentis biosimilar injection•FDA clears Heidelberg's new SPECTRALIS software release•Alkeus begins dosing in global phase 3 Stargardt trial on oral gildeuretinol•Alvotech resubmits BLA for proposed Eylea biosimilar•CooperVision completes global enrollment for largest pediatric myopia control study•FDA approves Lupin's Lucentis biosimilar injection
HEADLINES
FEATURED
The first and only topical immunomodulator approved for patients with VKC makes its comeback to the U.S. market under the Harrow name.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
